Introduction
============

Acute myocardial infarction (AMI) is one of the most common cardiovascular events, affecting \~7.9 million adults in the United States ([@r31]) and 540,000 in Canada ([@r10]).

Once people develop an AMI, their chances of long-term survival and their quality of life are reduced substantially ([@r31]). Recent studies have shown that people with an AMI had induced ST segment depression ([@r24]), decreased heart-rate variability ([@r26]; [@r42]), and increased ischemic events ([@r29]) within several days after exposure to elevated levels of air pollution. People with an AMI have also been found to be at higher risk of dying when daily pollution levels increase, particularly with particulate matter ≤ 10 μm in diameter (PM~10~) ([@r2]; [@r3]; [@r40]). These findings are supported by toxicological studies linking pollution with increased systemic oxidative stress and inflammation, blood coagulability, progression of atherosclerosis, and reduced heart-rate variability ([@r6]), indicating that AMI patients may be particularly sensitive to air pollution exposure ([@r25]; [@r33]).

Little is known, however, about the influence of long-term (months to years) exposure to air pollution on mortality after AMI, although there is increasing evidence that long-term exposures result in substantially larger health risks than exposures over several days ([@r6]). Among a small set of studies that have assessed the influence of long-term exposure to air pollution on mortality after AMI, three studies reported increased all-cause mortality in association with exposure to PM~2.5~ (particles ≤ 2.5 μm in diameter) ([@r35]), PM~10~ ([@r43]), and elemental carbon (C) ([@r39]). However, in two other studies, no compelling evidence was found for associations with PM~2.5~ ([@r16]) or nitrogen dioxide (NO~2~) ([@r32]). Because cause-of-death information was unavailable in previous studies ([@r35]; [@r39]; [@r43]), the specificity of the association between air pollution and post-AMI mortality remains uncertain; understanding this association would be helpful for elucidating pathways linking long-term exposure with survival in this subpopulation.

Therefore, we conducted a population-based cohort study to evaluate the impact of long-term exposure to PM~2.5~ on survival among AMI patients. In addition, we sought to quantify the burden of post-AMI mortality attributed to PM~2.5~. Given the high prevalence of AMI and the ubiquity of air pollution, such information may help target interventions to improve outcomes for AMI patients.

Methods
=======

Study Design and Study Population
---------------------------------

We conducted a cohort study of newly admitted AMI patients participating in Phase 1 of the Enhanced Feedback For Effective Cardiac Treatment (EFFECT) study (1999--2001) ([@r36]), a large randomized trial in Ontario, Canada. Details of the EFFECT study have been presented elsewhere ([@r36]). Briefly, that study included all patients admitted to one of 86 hospital corporations in Ontario with a primary or most responsible diagnosis of AMI (*International Classification of Diseases, Ninth Revision*, ICD-9 code 410). Trained nurses abstracted demographic (e.g., marital status) and clinical (e.g., smoking status, laboratory tests, and medical history) information from patients' primary charts. After we reviewed the medical records, patients who *a*) fulfilled the European Society of Cardiology/American College of Cardiology clinical criteria ([@r1]), *b*) had AMI onset before arriving at the hospital, and *c*) were registered with Ontario's provincial health insurance plan were included ([@r36]). Patients transferred from other acute-care facilities were excluded.

We restricted the study population to those who were ≥ 35 years of age at hospital admission, had a length of hospital stay of ≥ 2 days, and were Canadian-born individuals. Consistent with previous studies of air pollution and post-AMI survival ([@r3]; [@r32]; [@r35]; [@r40]), we further restricted the study population to those who were alive for ≥ 28 days after hospital discharge.

The Research Ethics Board of Sunnybrook Health Sciences Center, Toronto, approved the study.

Outcomes
--------

The follow-up period was from the 29th day after discharge in 1999--2001 until the end of 2011. We ascertained the underlying cause of death and the date of death using record linkage to the Ontario Registrar General's Death database using the patient\'s unique, encrypted health card number (linkage rate: 98%). The primary outcome was nonaccidental mortality (ICD-9 codes are listed in Table S1). To evaluate the specificity of the association between air pollution and mortality, we also ascertained deaths from any cardiovascular disease, ischemic heart disease, and AMI. In addition, to detect possible bias because of unmeasured confounding and other errors that may lead to spurious inference, we considered negative control outcomes for which no (or weaker) associations with air pollution were expected ([@r20]). To do this, we identified deaths from accidental causes and from noncardiopulmonary, non--lung cancer causes ([@r15]).

Assessment of Ambient Concentrations of PM~2.5~
-----------------------------------------------

Estimates of ground-level concentrations of PM~2.5~ were derived from satellite observations of aerosol optical depth \[sources of AOD are publicly available and were downloaded from <ftp://ladsweb.nascom.nasa.gov> (MODIS Terra and Aqua) and <ftp://l4ftl01.larc.nasa.gov> (MISR); the data were obtained over several years up to 2013, and version control maintained consistency throughout the access period\], a measure of light extinction by aerosols in the total atmospheric column, in conjunction with outputs from a global atmospheric chemistry transport model (GEOS-Chem CTM) ([@r37]). We used estimates from 2001 to 2010, thus obtaining 10-year mean concentrations of PM~2.5~ at a resolution of approximately 10 km × 10 km and covering North America below 70°N, which includes all of Ontario ([Figure 1](#f1){ref-type="fig"}). These satellite-based estimates of PM~2.5~ are in good accord with ground measurements at fixed-site stations across North America (Pearson correlation coefficient *r* = 0.76, *n* = 974) ([@r37]), and they improve the accuracy and spatiotemporal coverage of our earlier satellite-based estimates of PM~2.5~ ([@r38]), which have been used to determine the associations of PM~2.5~ with mortality and morbidity ([@r9]; [@r12]), as well as the global disease burden attributable to air pollution ([@r19]).

![Mean satellite-derived estimates of PM~2.5~ across Ontario, Canada, 2001--2010.](EHP185.g001){#f1}

The location of residence for each participant during the follow-up period was obtained from the Registered Persons Database, a registry of all Ontario residents with health insurance ([@r9]). Locations were refined to the spatial scale provided by six-character postal codes, which in urban areas represent a city block or a large apartment complex. We created annual estimates of exposure to PM~2.5~ for each participant by interpolating the 10-year mean concentrations of PM~2.5~ to the centroid of their residential postal code for that year, thereby accounting for residential mobility. This approach assumed that the spatial pattern in PM~2.5~ did not change appreciably during follow-up ([@r23]; [@r27]). This assumption is reasonable because we have shown previously that areas in Ontario with high concentrations of PM~2.5~ have retained their spatial ranking from 1996 to 2010 and that variability in long-term exposure to PM~2.5~ is primarily spatial rather than temporal ([@r9]).

Covariates
----------

We selected *a priori* the following potential confounders, abstracted from medical records: age, sex, marital status, employment status (employed/unemployed/retired/homemaker/disabled), major cardiac risk factors \[including smoking status, family history of coronary artery disease, diabetes, hyperlipidemia, hypertension, stroke, previous AMI, and previous percutaneous coronary intervention (PCI)\], AMI type \[ST elevation/non-ST elevation (STEMI/non-STEMI)\], acute pulmonary edema, selected comorbidities (including angina, cancer, dementia, dialysis, and chronic obstructive pulmonary disease), and cardiovascular medications at hospital discharge \[including statins, aspirin, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers\]. To assess in-hospital care, we obtained information about the length of hospital stay (days) and the characteristics of attending physicians (cardiologist/internist/family physician) and hospitals (teaching/community/small) ([@r36]). In addition, to assess the severity of the AMI, we calculated the Global Registry of Acute Cardiac Events (GRACE) risk score based on age, history of congestive heart failure and AMI, heart rate, systolic blood pressure, and several other prognostic variables ([@r4]). We also derived body mass index (BMI; kg/m^2^) using self-reported height and weight.

Using 2001 Canadian census-tract data (see Supplemental Material, "Canadian Census Divisions and Census Tracts"), we derived three neighborhood-level variables: *a*) percentage of population ≥ 15 years of age with less than high school education; *b*) unemployment rate; and *c*) mean household income. To control for region-scale spatial patterns in mortality that might be caused by factors other than pollution, we created a dichotomous variable classifying Ontario into the Greater Toronto area, a densely-populated urban megaregion, and all other areas. Toronto tends to differ from other areas in Ontario with respect to socioeconomic and demographic characteristics, health care, and mortality rates (see Table S2).

Statistical Analysis
--------------------

Standard and multilevel spatial random-effects Cox proportional hazards models ([@r21]) were used to assess post-AMI mortality in relation to PM~2.5~. The spatial random-effects model accounted for the possibility that patterns of health of residents living in the same or neighboring communities were more similar than for individuals living further apart and that these patterns may not be completely explained by variables included in the model. This modeling approach has been used extensively in previous studies of pollution-related mortality in the United States ([@r15]; [@r27], [@r28]) and in Canada ([@r12]).

Consistent with previous studies ([@r12]), the random effects in our spatial random-effects Cox model were represented by two levels of spatial clusters, with a first cluster level defined by census divisions (equivalent to counties) and a second level defined by census tracts within census divisions. We assumed that two census divisions were correlated if they were adjacent, and we made the same assumption for adjacent census tracts within each census division. Census tracts in different census divisions were assumed to be uncorrelated.

We developed models for mortality from nonaccidental causes, cardiovascular (any, ischemic heart, AMI), and as negative controls, accidental and noncardiopulmonary, non--lung cancer causes. We stratified the baseline hazard function by single-year age groups and by region, allowing each category to have its own baseline hazard. We included participants with nonmissing information on exposure and covariates, except for marital status (\~3% of the cohort had unknown values), employment status (6%), smoking (12%), and BMI (41%), for which we created a separate category of missing values to avoid losing substantial statistical power.

We measured follow-up time (in days) from baseline until death (47%), ineligibility for provincial health insurance (2%), or end of follow-up (51%). We fitted PM~2.5~ as a time-varying variable by modeling time-weighted exposure from baseline until death, with weights for each individual defined by the time spent at each residence. We constructed a sequence of models including different potential confounding factors (see Figure S1). The final model included variables for sex, marital status, employment status, smoking status, family history of coronary artery disease, diabetes, hyperlipidemia, hypertension, stroke, previous PCI, previous AMI, GRACE risk score, AMI type, acute pulmonary edema, indicators for in-hospital care, medications at discharge, comorbidities, and ecological variables. We adjusted for regional variations in the ecological variables across Ontario using the average for each census division and the difference between the values for each census tract and the census division mean. Because of the considerable missing data for BMI (41%), we did not include it in the main model, but we considered it in a sensitivity analysis.

We tested for deviations from the proportional hazards assumption by adding the cross product of each variable to the natural logarithm of the time variable, but we did not find any violations of this assumption (*p* \> 0.05). We also verified the assumption of linearity for all continuous variables by using natural cubic spline functions with ≤ 4 degrees of freedom (df). We examined plots of concentration--response curves for PM~2.5~ and computed the Akaike Information Criteria (AIC) to determine whether the response function was nonlinear. Because there was no evidence of departure from linearity for the relationship between PM~2.5~ and mortality (see [Figure 2](#f2){ref-type="fig"}, see also Table S3), we report adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for each 10 μg/m^3^ increase of PM~2.5~ (referred to as HR~10~).
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Sensitivity Analyses
--------------------

We performed a series of sensitivity analyses by considering follow-up starting 1 year after discharge, controlling for BMI in a subcohort with complete information, restricting the analysis to those living outside Toronto, and controlling for population density at the census-division level. In addition, we further controlled for distance to nearest acute-care hospital using a natural cubic spline with 3 df, adjusted for coronary revascularization during follow-up as a time-varying variable, and adjusted for a categorical variable indicating the population size of participants' home communities (rural, \< 30,000, 30,000--99,999, 100,000--499,999, ≥ 500,000). We obtained information about coronary revascularization through data linkage to the Discharge Abstract Database and the Ontario Health Insurance Plan Claims Database ([@r9]).

In addition, to account for time trends in air pollution and mortality, we also controlled for calendar time using a natural cubic spline with 3 df. To investigate whether the hazard ratios might be influenced by any possible spatial dependence introduced by hospitals, we further added a frailty term (random effect) for hospitals to allow for the possibility that the effect estimates varied from hospital to hospital in the estimation of the main effect and its variance. A gamma distribution for random effect was assumed, with an exchangeable correlation structure within hospitals. We compared the models with and without a frailty term using the AIC. Furthermore, we additionally controlled for neighborhood-level deprivation, density of family physicians, and several other geographically variable sociodemographic and health care indicators; we also restricted to cohort members living between 41.7°N and 46.0°N, where the vast majority of the Ontario population resides, and to those living within 5 km of any manufacturing or process facilities releasing particulate matter (see Supplemental Material, "Additional Sensitivity Analyses").

Lastly, we investigated *a priori* whether individuals with preexisting angina, AMI, diabetes, and hypertension were at greater risk, as well as testing for potential effect modification by AMI type (STEMI/non-STEMI) and medication use, by assessing whether the interaction term that was the cross-product of each variable with the PM~2.5~ value was statistically significant.

Burden Attributable to PM~2.5~
------------------------------

To quantify the burden of death attributed to long-term exposure to PM~2.5~ among those with AMI, we estimated the number of deaths caused by PM~2.5~ with reference to an alternative (counterfactual) distribution of exposure (i.e., the minimum that could be achieved at the population level). For this procedure, we chose the lowest concentration of PM~2.5~ measured across all cities worldwide (4 μg/m^3^) ([@r5]). We then derived the attributable fraction and applied it to the number of nonaccidental deaths during follow-up (see Supplemental Material, "Burden Attributable to PM~2.5~"). We used the hazard ratio from the fully adjusted spatial random-effects model. To estimate the 95% uncertainty interval, we sampled the 2.5th and 97.5th percentile of 1,000 draws from the distribution of exposure and the hazard ratio using the approach reported in the Global Burden of Disease Study 2010 ([@r19]).

Analyses were performed using the R statistical package (v.3.0.0, 64-bit) ([@r30]). The spatial random-effects Cox model was fitted using the Cox-Poisson program ([@r17]).

Results
=======

Among the 10,386 eligible patients from the EFFECT study, we excluded 84 (\~1%) patients who were \< 35 years old, 379 (4%) whose length of hospital stay was \< 2 days, 281 (3%) who were landed immigrants, 284 (3%) who died within 28 days post-discharge, and 485 (5%) with missing data on covariates except for marital status, employment status, smoking, and BMI, leaving a total of 8,873 patients in our analytical cohort.

At the time of entry, the mean age was 66.9 years, 65% were men, and 36% were current smokers ([Table 1](#t1){ref-type="table"}). Of the cohort, 23% had a prior AMI, nearly half had been diagnosed with STEMI, and 34.5% were prescribed statins at discharge. Average unemployment among the census tracts was 6%, and the mean household income was 52,400 CAD.

###### 

Baseline characteristics of the study population.

  Baseline characteristics^*a*^                                                                                                                                                                                Cohort (*n* = 8,873)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------
  Demographic characteristics                                                                                                                                                                                  
  Age, years                                                                                                                                                                                                   66.9 ± 13.0
  Men, %                                                                                                                                                                                                       65
  Marital status, %                                                                                                                                                                                            
  Married                                                                                                                                                                                                      68
  Single                                                                                                                                                                                                       6
  Separated, widowed, or divorced                                                                                                                                                                              23
  Unknown                                                                                                                                                                                                      3
  Employment, %                                                                                                                                                                                                
  Employed/self                                                                                                                                                                                                26
  Homemaker                                                                                                                                                                                                    3
  Retired                                                                                                                                                                                                      62
  Unemployed                                                                                                                                                                                                   1
  Disabled                                                                                                                                                                                                     2
  Unknown                                                                                                                                                                                                      6
  Cardiac risk factors and history                                                                                                                                                                             
  Smoking, %                                                                                                                                                                                                   
  Never smoker                                                                                                                                                                                                 28
  Current smoker                                                                                                                                                                                               36
  Former smoker                                                                                                                                                                                                24
  Unknown                                                                                                                                                                                                      12
  Body mass index, kg/m^2^                                                                                                                                                                                     27.9 ± 5.5
  \< 18.5 (%)                                                                                                                                                                                                  1
  18.5--24.9 (%)                                                                                                                                                                                               17
  25.0--29.9 (%)                                                                                                                                                                                               25
  ≥ 30.0 (%)                                                                                                                                                                                                   16
  Unknown (%)                                                                                                                                                                                                  41
  Family history of coronary artery disease, %                                                                                                                                                                 33
  Diabetes, %                                                                                                                                                                                                  25
  Hyperlipidemia, %                                                                                                                                                                                            32
  Hypertension, %                                                                                                                                                                                              46
  Previous percutaneous coronary intervention, %                                                                                                                                                               3
  Previous myocardial infarction, %                                                                                                                                                                            23
  Stroke, %                                                                                                                                                                                                    7
  GRACE risk score                                                                                                                                                                                             142 ± 36
  Comorbidities, %                                                                                                                                                                                             
  Angina                                                                                                                                                                                                       32
  Cancer                                                                                                                                                                                                       3
  Dementia                                                                                                                                                                                                     3
  Dialysis                                                                                                                                                                                                     1
  Chronic obstructive pulmonary disease                                                                                                                                                                        1
  Clinical risk parameters, %                                                                                                                                                                                  
  ST elevation myocardial infarction                                                                                                                                                                           49
  Acute pulmonary edema                                                                                                                                                                                        5
  In-hospital care                                                                                                                                                                                             
  Length of stay, days                                                                                                                                                                                         8.0 ± 7.8
  Specialty of attending physician, %                                                                                                                                                                          
  General practice                                                                                                                                                                                             34
  Internal medicine                                                                                                                                                                                            31
  Cardiology                                                                                                                                                                                                   35
  Characteristics of hospitals, %                                                                                                                                                                              
  Teaching                                                                                                                                                                                                     13
  Community                                                                                                                                                                                                    80
  Small                                                                                                                                                                                                        7
  Cardiovascular medication at discharge, %                                                                                                                                                                    
  Statins                                                                                                                                                                                                      35
  Aspirin                                                                                                                                                                                                      78
  ACE inhibitor                                                                                                                                                                                                55
  Beta-blockers                                                                                                                                                                                                70
  Area-level characteristics^*b*^                                                                                                                                                                              
  Percentage population aged ≥ 15 years with less than a high school education                                                                                                                                 29
  Percentage population aged ≥ 15 years without employment                                                                                                                                                     6
  Average household income (1,000 CAD)                                                                                                                                                                         52.4 ± 23.7
  Abbreviations: ACE, angiotensin-converting enzyme; GRACE, Global Registry of Acute Coronary Events. ^***a***^Values are percent or mean ± standard deviation. ^***b***^At the Canadian census-tract level.   

The cohort contributed 72,101 person-years of observation, with a mean follow-up of 8.1 years. During the follow-up period, \~39% of participants changed addresses, and 22% moved out of the city that they had lived in when they enrolled. The average concentration of PM~2.5~ according to participants' residences at baseline was 10.7 μg/m^3^ (range, 2.2--16.5), with the highest average concentrations in southern Ontario ([Figure 1](#f1){ref-type="fig"}). Between 1999 and 2011, we identified 4,016 deaths from nonaccidental causes, of which 2,147 were from any cardiovascular disease, 1,650 were from ischemic heart disease, and 675 were from AMI. In addition, there were 121 deaths caused by accidents and 1,382 deaths from noncardiopulmonary, non--lung cancer causes.

We found a positive association for nonaccidental mortality using the standard Cox model, with a hazard ratio of 1.12 (95% CI: 0.98, 1.29) with each 10-μg/m^3^ increase in PM~2.5~, after adjusting for age and sex ([Table 2](#t2){ref-type="table"}). The corresponding HR~10~ from the random-effects model was 1.14 (95% CI: 0.99, 1.32). Controlling for smoking, diabetes, AMI type, GRACE risk score, medication use, and several other individual-level factors strengthened the association in both models (HR~10~ = 1.18 for the standard Cox model and HR~10~ = 1.20 for the random-effects model). In models adjusting for all individual- and neighborhood-level covariates, the HR~10~ from the standard Cox model was 1.21 (95% CI: 1.03, 1.41), and the HR~10~ from the random-effects model was 1.22 (95% CI: 1.03, 1.45). Because the estimates were similar for the two models, only results from the random-effects model are reported below because this model allowed for more accurate estimation of statistical error.

###### 

Association of non-accidental mortality with every 10-μg/m^3^ increase in PM~2.5~.

  Model                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Standard Cox model   Random-effects model^*a*^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- ---------------------------
  PM~2.5~ adjusted for sex and stratified by age and region^*b*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.12 (0.98, 1.29)    1.14 (0.99, 1.32)
  \+ Marital status, employment^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.14 (1.00, 1.30)    1.15 (1.00, 1.33)
  \+ Cardiac risk factors and history^*d*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1.16 (1.01, 1.33)    1.16 (0.99, 1.36)
  \+ Clinical severity parameters^*e*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.14 (0.99, 1.32)    1.14 (0.97, 1.34)
  \+ Length of stay, characteristics of physicians and hospitals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1.21 (1.05, 1.40)    1.22 (1.04, 1.43)
  \+ Medication use at hospital discharge^*f*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.20 (1.03, 1.39)    1.21 (1.03, 1.43)
  \+ Preexisting angina, cancer, dementia, COPD, dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1.18 (1.02, 1.36)    1.20 (1.02, 1.41)
  \+ Area-level variables^*g*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.21 (1.03, 1.41)    1.22 (1.03, 1.45)
  Abbreviations: CI, confidence interval; COPD; chronic obstructive pulmonary disease; PM~2.5~, particles ≤ 2.5 μm in diameter. ^***a***^A nested, spatial random-effects Cox model comprising two levels of spatial clusters: a first cluster level defined by census divisions and a second level by census tracts. ^***b***^Region: living or not in the Greater Toronto Area. ^***c***^Variables were added to the model including base model and all previous variables labeled with "+". ^***d***^Included smoking, family history of coronary artery disease, diabetes, hyperlipidemia, hypertension, stroke, previous percutaneous coronary intervention (PCI), acute myocardial infarction (AMI), and Global Registry of Acute Coronary Events (GRACE) risk score. ^***e***^Included ST elevation myocardial infarction (STEMI)/non-STEMI and acute pulmonary edema. ^***f***^Included statins, aspirin, angiotensin-converting enzyme (ACE) inhibitors, and beta-blockers. ^***g***^Included census-division level unemployment rate, education, and annual household income, as well as the subtraction of these variables at the census-tract level from their census-division mean.                        

In sensitivity analyses, the HR~10~ estimates were not appreciably altered after considering follow-up starting 1 year after discharge, adjusting for distance to nearest hospitals, adjusting for coronary revascularization during follow-up, adding a frailty term for hospitals to allow for potential spatial clustering, or other sensitivity analyses, with the exception of controlling for BMI ([Table 3](#t3){ref-type="table"}, see also Table S4). We found a stronger association for nonaccidental mortality in the subcohort with information on BMI (HR~10~ = 1.46, 95% CI: 1.18, 1.81), after further controlling for BMI.

###### 

Sensitivity analyses for the association of nonaccidental mortality with every 10-μg/m^3^ increase in PM~2.5~.

  Sensitivity analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Number of deaths   Nonaccidental mortality^*a*^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ ------------------------------
  Follow-up starting 1 year after discharge                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                3,301              1.19 (0.99, 1.40)
  Restricted to participants with complete data on BMI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2,213              1.46 (1.18, 1.81)
  Restricted to participants outside Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               3,046              1.28 (1.06, 1.58)
  Adjusted for population density^*b*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     4,016              1.30 (1.07, 1.58)
  Adjusted for distance to nearest acute-care hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     4,016              1.22 (1.03, 1.46)
  Adjusted for coronary revascularization during follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 4,016              1.22 (1.02, 1.44)
  Adjusted for long-term time trend in calendar year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       4,016              1.23 (1.03, 1.46)
  Adjusted for indicators for urban size^*c*^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              4,016              1.28 (1.06, 1.55)
  Added a random effect for hospitals to further investigate spatial dependency as a source of bias                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        4,016              1.21 (1.01, 1.46)
  Abbreviations: BMI, body mass index; CI, confidence interval, PM~2.5~; particles ≤ 2.5 μm in diameter. ^***a***^A nested, spatial random-effects Cox model, stratified by age and region, and adjusted for sex, marital status, employment, smoking, family history of coronary artery disease, diabetes, hyperlipidemia, hypertension, stroke, previous percutaneous coronary intervention (PCI), acute myocardial infarction (AMI), Global Registry of Acute Coronary Events (GRACE) risk score, ST elevation myocardial infarction (STEMI)/Non-STEMI, acute pulmonary edema, in-hospital care, medications, comorbidities, and area-level variables. ^***b***^At the Canadian census division level. ^***c***^Size of subjects' home community: rural/farm; small town (\< 30,000); Urban 3 (30,000--99,999); Urban 2 (100,000--499,999); and Urban 1 (\> 499,999).                      

We also observed stronger associations between PM~2.5~ exposure and mortality from cardiovascular disease (HR~10~ = 1.35, 95% CI: 1.09, 1.67), mortality from ischemic heart disease (HR~10~ = 1.43, 95% CI: 1.12, 1.83), and mortality from AMI (HR~10~ = 1.64, 95% CI: 1.13, 2.40) ([Table 4](#t4){ref-type="table"}). No association was found for mortality from accidental and noncardiopulmonary non--lung cancer causes. Furthermore, an analysis of selected subgroups did not provide compelling evidence supporting effect modification of PM~2.5~ by diabetes (*p*-interactions varied from 0.06 to 0.90 depending on the outcomes), AMI type (*p*-interactions: 0.07 to 0.33), statins (*p*-interactions: 0.43 to 0.98), and other selected characteristics.

###### 

Associations of cause-specific mortality with every 10-μg/m^3^ increase in PM~2.5~.

  Cause of death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ICD-9 code                      Number of deaths   Fully adjusted model^*a*^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------ ---------------------------
  Any cardiovascular                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 401--459                        2,147              1.35 (1.09, 1.67)
  Ischemic heart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     410--414                        1,650              1.43 (1.12, 1.83)
  Myocardial infarction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              410                             675                1.64 (1.13, 2.40)
  Non-cardiopulmonary, non-lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \< 401, 520--799, and not 162   1,382              1.06 (0.81, 1.39)
  Accidental                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ≥ 800                           121                1.07 (0.41, 2.76)
  Abbreviations: CI, confidence interval; ICD-9, *International Classification of Diseases*, Revision 9; PM~2.5~, particles ≤ 2.5 μm in diameter. ^***a***^A nested, spatial random-effects Cox model, stratified by age and region, and adjusted for sex, marital status, employment, smoking, family history of coronary artery disease, diabetes, hyperlipidemia, hypertension, stroke, previous percutaneous coronary intervention (PCI), acute myocardial infarction (AMI), Global Registry of Acute Coronary Events (GRACE) risk score, ST elevation myocardial infarction (STEMI)/Non-STEMI, acute pulmonary edema, in-hospital care, medications, comorbidities, and area-level variables.                                                      

Lastly, we calculated that the rate of mortality would be reduced by 12.4% (95% CI: 1.6%, 22.5%) if this cohort had been exposed to the lowest measured level of PM~2.5~ in an urban area as opposed to their present distribution of exposure. This estimate translates to 497 (95% CI: 65, 904) deaths attributable to elevated PM~2.5~ exposure in this cohort.

Discussion
==========

In this cohort study of AMI patients, exposure to ambient PM~2.5~ was associated with increased nonaccidental mortality, with HR~10~ varying between 1.21 (95% CI: 1.03, 1.41) and 1.22 (95% CI: 1.03, 1.45) depending on model structures. The association was robust to sensitivity analyses and appeared to be stronger for mortality from cardiovascular causes, particularly from ischemic heart disease (HR~10~ = 1.43) and AMI (HR~10~ = 1.64). Additionally, we did not find strong evidence for effect modification by selected characteristics such as comorbidities and secondary prevention measures. Overall, our estimated association of PM~2.5~ and mortality translates to 497 deaths in this cohort (or 12.4% of nonaccidental deaths) that could have been averted if the lowest measured PM~2.5~ concentration in an urban area (4 μg/m^3^) had been achieved over the course of the study.

Few studies have investigated the relationship between post-AMI mortality and long-term air pollution exposure. In a cohort study of 154,204 AMI survivors in England and Wales with follow-up from 2004 to 2010, [@r35] reported an adjusted HR~10~ of all-cause mortality with PM~2.5~ of 1.20 (95% CI: 1.04, 1.38) and an HR of 1.01 (95% CI: 0.98, 1.04) per 10 μg/m^3^ of NO~2~. A second study of 1,120 AMI survivors in central Israel reported a positive but statistically nonsignificant association of PM~2.5~ with post-AMI mortality (HR~10~ = 1.3, 95% CI = 0.8, 2.1) ([@r16]). Similarly, two separate cohort studies in the United States linked increased all-cause deaths among AMI patients to PM~10~ ([@r43]) and elemental carbon (a proxy for traffic particles) ([@r39]). In contrast, no association was found for NO~2~ with post-AMI survival in an Italian cohort of AMI patients ([@r32]).

Our risk estimates for PM~2.5~ and mortality appeared higher than those reported previously from cohort studies based on general populations ([@r8]; [@r12]; [@r14]; [@r15]; [@r18]; [@r28]). In a Canadian national cohort study following 2.1 million adults over 1991--2001, [@r12] reported positive associations of PM~2.5~ and mortality from nonaccidental causes (HR~10~ = 1.15), any cardiovascular disease (HR~10~ = 1.16), and ischemic heart disease (HR~10~ = 1.31). A meta-analysis of 11 cohort studies examining air pollution and cardiovascular-related mortality reported a pooled HR~10~ of 1.11 (95% CI: 1.05, 1.16) for PM~2.5~ ([@r14]). Although there is some overlap in estimates of risk between the present study and these previous studies ([@r8]; [@r12]; [@r14]; [@r18]; [@r28]), the higher risk estimates observed in the present cohort, particularly for cardiovascular-related mortality, suggest that AMI survivors are more susceptible to air pollution than the general population. It is noteworthy that ambient concentrations of PM~2.5~ in Ontario (annual mean in 2000: 11.2 μg/m^3^) were considerably lower than those observed in many cities in the United States (e.g., annual mean PM~2.5~ in Los Angeles: 20.7 μg/m^3^ in 2000) ([@r11]), in Europe (e.g., Rome, Italy: 19.9 μg/m^3^ in 2010) ([@r8]), and in Asia (e.g., Beijing, China: 56.0 μg/m^3^ in 2010; Delhi, India: 153.0 μg/m^3^ in 2013) ([@r41]). Given that billions of people worldwide are exposed to high concentrations of PM~2.5~ and that the relationship between mortality and PM~2.5~ was similar over a range of exposures in the present study and in previous studies ([@r7]), our findings have important global public health implications. Our findings imply that important health benefits can be achieved through efforts to further reduce ambient air pollution worldwide.

We did not find strong evidence that comorbidities and medications altered the association between PM~2.5~ and mortality because the power to detect such differences was limited. Cardiovascular medications such as statins improve endothelial function, modulate inflammatory responses, maintain plaque stability, and prevent thrombus formation, all of which potentially protect against the effects of PM~2.5~ ([@r13]; [@r22]; [@r34]). Further investigation of potential interactions between cardiovascular medications and air pollution exposure in post-AMI survival is merited given the widespread use of these medications by this subpopulation.

The strengths of this study include its relatively large size and population-based representation of AMI patients in Ontario, the most populous province in Canada. In addition, we obtained extensive individual-level information including detailed clinical data and demographic and behavioral characteristics, which allowed for good control for known risk factors. Aspects of our analytic approach also reduced concerns about confounding, such as the use of spatial random-effects models. The standard Cox model yielded smaller estimates of the standard error for PM~2.5~ than those produced by the spatial random-effects model, suggesting that there was unexplained spatial variation in mortality within the cohort. By specifying nested spatial clusters to account for possible spatial dependencies among participants, the spatial random-effects models improved the estimation of the standard error for PM~2.5~ effects. In addition, our study benefited from having information on cause of death, allowing the association between PM~2.5~ and mortality to be analyzed in great detail. Furthermore, the use of satellite-based long-term average estimates of PM~2.5~ ensured virtually complete spatial coverage of PM~2.5~ exposure for the cohort.

Several limitations merit mention. First, we lacked information on individual socioeconomic status (SES) such as income and education. However, we controlled for smoking, employment status, area-level SES, and comorbidities, which may partly lie in the causal pathway between individual SES and post-AMI mortality (see Figure S1). Although we cannot rule out the possibility of residual confounding by individual SES, it is unlikely that this would substantially bias our risk estimates, and the null association with negative control outcomes did not support this possibility.

Second, the spatial pattern of PM~2.5~ was derived for the period 2001 to 2010, covering most of the follow-up period (1999--2011). We have shown previously that the spatial gradients of ambient PM~2.5~ in Ontario are stable over time and that variability in PM~2.5~ concentrations is primarily spatial rather than temporal ([@r9]). Because 78% of cohort members never moved or moved only within the city of residence, the spatial contrasts in PM~2.5~ over 2001--2010 are expected to be a reasonable representation of longer-term spatial exposures to PM~2.5~ in Ontario ([@r9]).

Third, the 10 km × 10 km resolution of the satellite-based exposure surface reduced our ability to capture the fine-scale intraurban variation in PM~2.5~ exposures that tends to occur in areas with relatively high PM~2.5~ concentrations. This low resolution may result in larger uncertainties in characterizing the concentration--response relationship at the higher end of PM~2.5~ exposures. We also did not have information on daily activity. Given the inherent imprecision of the spatially derived exposure, our assessment of exposure was likely subject to nondifferential misclassification that may have attenuated the estimates. In addition, our analyses did not consider the mixture of air pollutants to which subjects may have been exposed.

Fourth, information on most potential confounding variables was obtained at baseline only. Although we adjusted for medications at discharge and coronary revascularization during follow-up, we could not further account for post-discharge medications because the information was unavailable.

In this study, the strongest associations with PM~2.5~ appeared to be for cardiovascular-related mortality, particularly from ischemic heart disease. This finding supports that the biological pathways involved in the cardiovascular effects of PM~2.5~ ([@r6]), including systemic oxidative stress and inflammation, increased blood coagulability, enhanced thrombosis, and vascular dysfunction, may have played an important role in increasing post-AMI mortality. These responses may have a large impact on individuals who already have compromised cardiovascular systems, such as AMI patients.

Conclusions
===========

In summary, this study adds weight to previous observations that AMI patients are susceptible to the effects of air pollution, and it provides new evidence that the survival of AMI patients may be significantly influenced by long-term exposure to PM~2.5~, even at the relatively low levels observed in Ontario.
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